Ligand activation mechanisms of human KCNQ2 channel.
Demin MaYueming ZhengXiaoxiao LiXiaoyu ZhouZhenni YangYan ZhangLong WangWenbo ZhangJiajia FangGuohua ZhaoPanpan HouFajun NanWei YangNannan SuZhaobing GaoJiangtao GuoPublished in: Nature communications (2023)
The human voltage-gated potassium channel KCNQ2/KCNQ3 carries the neuronal M-current, which helps to stabilize the membrane potential. KCNQ2 can be activated by analgesics and antiepileptic drugs but their activation mechanisms remain unclear. Here we report cryo-electron microscopy (cryo-EM) structures of human KCNQ2-CaM in complex with three activators, namely the antiepileptic drug cannabidiol (CBD), the lipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ), and HN37 (pynegabine), an antiepileptic drug in the clinical trial, in an either closed or open conformation. The activator-bound structures, along with electrophysiology analyses, reveal the binding modes of two CBD, one PIP 2 , and two HN37 molecules in each KCNQ2 subunit, and elucidate their activation mechanisms on the KCNQ2 channel. These structures may guide the development of antiepileptic drugs and analgesics that target KCNQ2.
Keyphrases
- endothelial cells
- clinical trial
- high resolution
- electron microscopy
- induced pluripotent stem cells
- pluripotent stem cells
- randomized controlled trial
- emergency department
- gene expression
- genome wide
- dna methylation
- inflammatory response
- single cell
- study protocol
- subarachnoid hemorrhage
- brain injury
- molecular dynamics simulations
- blood brain barrier
- nuclear factor
- adverse drug
- electronic health record
- protein kinase
- toll like receptor
- cerebral ischemia